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Background: In B-cell precursor acute lymphoblastic leukaemia (B-ALL), the identification of additional genetic alterations
associated with poor prognosis is still of importance. We determined the frequency and prognostic impact of somatic mutations in
children and adult cases with B-ALL treated with Spanish PETHEMA and SEHOP protocols.
Methods: Mutational status of hotspot regions of TP53, JAK2, PAX5, LEF1, CRLF2 and IL7R genes was determined by next-
generation deep sequencing in 340 B-ALL patients (211 children and 129 adults). The associations between mutation status and
clinicopathological features at the time of diagnosis, treatment outcome and survival were assessed. Univariate and multivariate
survival analyses were performed to identify independent prognostic factors associated with overall survival (OS), event-free
survival (EFS) and relapse rate (RR).
Results: A mutation rate of 12.4% was identified. The frequency of adult mutations was higher (20.2% vs 7.6%, P¼ 0.001). TP53 was
the most frequently mutated gene (4.1%), followed by JAK2 (3.8%), CRLF2 (2.9%), PAX5 (2.4%), LEF1 (0.6%) and IL7R (0.3%).
All mutations were observed in B-ALL without ETV6-RUNX1 (P¼ 0.047) or BCR-ABL1 fusions (Po0.0001). In children, TP53mut was
associated with lower OS (5-year OS: 50% vs 86%, P¼ 0.002) and EFS rates (5-year EFS: 50% vs 78.3%, P¼ 0.009) and higher RR
(5-year RR: 33.3% vs 18.6% P¼ 0.037), and was independently associated with higher RR (hazard ratio (HR)¼ 4.5; P¼ 0.04). In adults,
TP53mut was associated with a lower OS (5-year OS: 0% vs 43.3%, P¼ 0.019) and a higher RR (5-year RR: 100% vs 61.4%, P¼ 0.029),
whereas JAK2mut was associated with a lower EFS (5-year EFS: 0% vs 30.6%, P¼ 0.035) and a higher RR (5-year RR: 100% vs 60.4%,
P¼ 0.002). TP53mut was an independent risk factor for shorter OS (HR¼ 2.3; P¼ 0.035) and, together with JAK2mut, also were
independent markers of poor prognosis for RR (TP53mut: HR¼ 5.9; P¼ 0.027 and JAK2mut: HR¼ 5.6; P¼ 0.036).
Conclusions: TP53mut and JAK2mut are potential biomarkers associated with poor prognosis in B-ALL patients.
B-cell precursor acute lymphoblastic leukaemia (B-ALL) is a
malignancy of lymphoid progenitor cells, characterised by large
biological and clinical heterogeneity (Roberts and Mullighan,
2015). ALL is the most frequent childhood cancer and also
accounts for B25% of adult acute leukaemias (Bhojwani et al,
2015). High-risk B-ALL disease is more likely with adults than
*Correspondence: Dr J-M Hernández-Rivas; E-mail: jmhr@usal.es
18These authors contributed equally to this work.
Received 5 March 2017; revised 26 April 2017; accepted 8 May 2017
r 2017 Cancer Research UK. All rights reserved 0007 – 0920/17
FULL PAPER
Keywords: acute lymphoblastic leukaemia (ALL); next-generation sequencing (NGS); prognosis; outcome;
survival; TP53; JAK2; mutation
British Journal of Cancer (2017), 1–10 | doi: 10.1038/bjc.2017.152
www.bjcancer.com | DOI:10.1038/bjc.2017.152 1Advance Online Publication: 30 May 2017
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by Gestion del Repositorio Documental de la Universidad de Salamanca
children, and the long-term disease-free adult survival rates are
o40%, despite intensive chemotherapy and/or allogeneic stem cell
transplantation treatments. This is in stark contrast to pediatric
ALL, in which refined treatment regimens have resulted in cure
rates approaching 80% (Paulsson et al, 2008; Bhojwani et al, 2015).
However, in spite of this high cure rate, some children with ALL
have a poor outcome, whereby 15% of them die from ALL relapses
(Gowda and Dovat, 2013).
To date, the prognosis of B-ALL patients has focused mainly on
clinical, haematological and genetic factors, such as age, leukocyte
count at diagnosis, percentage of blast in peripheral blood,
immunophenotype, central nervous system involvement, cytoge-
netic and molecular alterations and the presence of minimal
residual disease (MRD), the latter two characteristics being most
strongly associated with prognosis (Izraeli, 2010; Pui et al, 2011;
Salari et al, 2014; Schrappe, 2014). However, B30% of pediatric
and 50% of adult ALL patients lack defined genetic hallmarks
of biological and clinical significance (Bungaro et al, 2009;
Dawson et al, 2011; Forero-Castro et al, 2016a; Forero-Castro
et al, 2016b). Somatic mutations are hallmarks of lymphoid
malignancies, and each genetic subtype harbours hidden mutations
that are strong independent predictors of outcome (Iacobucci et al,
2012).
In recent years, the use of next-generation sequencing (NGS)
has greatly increased the ability to identify somatic mutations with
clinical impact in both child and adult B-ALL. These mutations
involved genes associated with RAS signalling (48%; e.g., NRAS,
KRAS, PTPN11, FLT3, BRAF and NF1), B-cell differentiation and
development (18%; e.g., PAX5, IKZF1, EBF1, VPREB1), JAK/STAT
signalling (11%; e.g., JAK1, JAK2, IL7R and CRLF2), cell cycle
regulation and tumour suppression (6%; e.g., TP53, RB1,
CDKN2A/B, PTEN and BTG1), and non-canonical pathways
(9%, e.g., ETV6, CREBBB and TBL1XR1) (Harrison, 2011;
Mullighan, 2011; Pui et al, 2011; Roberts and Mullighan, 2011;
Iacobucci et al, 2012; Loh and Mullighan, 2012; Gowda and Dovat,
2013; Inaba et al, 2013; Chiaretti et al, 2014a; Chiaretti et al, 2014b;
Woo et al, 2014). However, the prognostic impact of these
mutations as predictors of clinical course, outcome and response to
therapy is still being explored.
Herein, the frequency and clinical relevance of somatic
mutations within a selected custom panel of six genes, TP53,
JAK2, IL7R, PAX5, LEF1 and CRLF2 exons, was examined.
Targeted exonic regions with known mutational hotspots
(Harrison, 2011; Iacobucci et al, 2012; Inaba et al, 2013; Roberts
and Mullighan, 2015), were analysed by amplicon-based NGS in
340 B-ALL patients. We demonstrated that mutations in TP53 and
JAK2 have a negative impact on the outcome of pediatric and adult
patients. This supports their role as prognostic biomarkers, and
suggests that if assessed at diagnosis, they might contribute to a
better risk stratification of B-ALL patients.
MATERIALS AND METHODS
Patients and data collection. A total of 340 B-ALL patients
referred from 22 Spanish centres to the Hematology Service at the
Salamanca University Hospital, Spain, between February 1996 and
February 2015 were eligible for this study. Two hundred and eleven
of the patients were children (62.1%, o18 years) and 129 were
adults (37.9%, X18 years).
The diagnosis of B-ALL was based on morphological,
immunophenotypic and genetic features of leukaemic blast cells,
as described previously (Pui and Evans, 1998). Conventional
cytogenetic analyses, fluorescent in situ hybridisation, demo-
graphic information, clinical characteristics, risk classification,
frontline therapy protocol, response to therapy and survival were
recorded. The criteria for defining and categorising the primary
chromosomal abnormalities were established according to a
previous study (Forero-Castro et al, 2016a), and are showed in
Supplementary Material file 1. Patients were treated according to
PETHEMA (Programa Español de Tratamientos en Hematologı́a)
and SEHOP (Sociedad Española de Hematologı́a y Oncologı́a
Pediátrica) risk-adapted protocols. The study was approved by the
local ethical committee, ‘The Comité Ético de Investigación Clı́nica
del área de salud de Salamanca’, at the Hospital Universitario de
Salamanca. Written informed consent was obtained from each
patient or legal guardians before patients entered the study.
DNA isolation. Amplicon-based NGS was performed on all 340
samples obtained from untreated patients at diagnosis. Genomic
DNA was extracted from frozen bone marrow or fixed peripheral
blood cell samples with the QIAmp DNA Mini Kit (Qiagen,
Valencia, CA, USA) following the manufacturer’s instructions.
Next-generation amplicon deep-sequencing assay. An amplicon-
based NGS assay was applied, using Titanium amplicon chemistry
on a 454-GS Junior DNA Sequencing Platform (454 Life Sciences,
Branford, CT, USA). With this approach, preconfigured custom
96-well primer plates containing lyophilised primer pairs (Roche,
Branford, CT, USA) were used to prepare the amplicon library
following the IRON-II Study procedures from the European
Leukaemia Network group (Kohlmann et al, 2011). Nineteen
hotspot exons were amplified: TP53 (E4-E11), JAK2 (E12-E16),
PAX5 (E2-E3), LEF1 (E2-E3), CRLF2 (E6) and IL7R (E5). The size
of amplicons ranged from 304 to 431 bp including the adaptor
sequences (see Supplementary Material File 1: Supplementary
Table S1 for primer sequences). Information about amplicon
library pooling, purification, emulsion PCR, sequencing, validation
of variants, data processing and analysis, is presented in the
Supplementary Material File 1.
CRLF2 gene expression analysis. In a subset of 97 B-ALL patients
(81 children and 16 adults) the expression levels of CRLF2 were
evaluated by quantitative RT-PCR assays. CRLF2-overexpressed
samples were identified as previously described (Yoda et al, 2010)
(see Supplementary Material file 1 for further details).
Statistical methods. Continuous variables were summarised as
their median and range; categorical variables were described as the
frequency and percentage of subjects in each category. Associations
between the presence of mutations and the values of clinical
parameters were investigated. Continuous variables were analysed
by the non-parametric Mann–Whitney U-test. The w2 or Fisher’s
exact tests were used to identify significant associations between
dichotomous variables, as appropriate. All tests were two-sided and
values of Po0.05 were considered to be significant. Kaplan–Meier
analysis (log-rank test) was used to assess the relationship between
mutations and overall survival (OS), event-free survival (EFS) and
relapse rate (RR). Survival rates were given as probabilities of
survival at 5 years, with a 95% confidence interval (CI). Pediatric
and adult patients were analysed separately. Survival criteria are
shown in the Supplementary Material File 1. Clinical and genetic
variables were first analysed by univariate analysis, and those with
a P-value up to 0.05 were included in multivariate analysis.
A multivariate Cox proportional hazards regression model was
used to estimate the hazard ratio (HR) and 95% CI of risk factors.
Specifically simultaneous regression, which SPSS calls the Enter
method was used. Analyses were performed using SPSS version
22.0 (IBM).
RESULTS
Patient characteristics. Table 1 shows the clinical characteristics
of the pediatric and adult patients with B-ALL included in this
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study. The median age was 12 years (range 0–84 years); childhood
patients were aged from 0 to 17 years (median 5 years) while adult
patients were aged from 18 to 84 years (median 45 years). The
median percentage of blast counts in bone marrow was 90%
(range, 35–100%) and 30.6% of patients showed normal cytoge-
netics. The presence of poor prognosis abnormalities t(9;22)
(Phþ ), t(v;11q23) and hypodiploidy, were more frequent in adult
than in childhood B-ALL (48.8% vs 8.1%, Po0.0001). In addition,
there was a higher prevalence of highly hyperdiploid cases (450
chromosomes) in the pediatric compared with the adult group
(15.6% vs 3.9%, P¼ 0.001). The median follow-up of the whole
series was 60 months (range, 2–186 months). The children had
higher rates of 5-year OS (85.3% vs 40.5%, Po0.0001), EFS (77.7%
vs 28.6%, Po0.0001) and relapse (RR) (16.1% vs 48.1%,
Po0.0001) compared with adults.
Frequency and characterisation of molecular mutations in
B-ALL. Thirty different mutations were observed in 42 out of
the 340 patients at diagnosis (12.4%). TP53 was the most
frequently mutated gene, being present in 4.1% of patients,
followed by JAK2 (3.8%), CRLF2 (2.9%), PAX5 (2.4%), LEF1
(0.6%) and IL7R (0.3%). The mutations were more frequent in
adults than in children (20.2% vs 7.6%, P¼ 0.001). The detailed
frequency of mutations in children and adults was TP53 (2.4% vs
7.0%, P¼ 0.038), CRLF2 (0.5% vs 7.0%, P¼ 0.001), JAK2 (2.4% vs
6.2%, P¼ 0.086), PAX5 (1.4% vs 3.9%, P¼ 0.162), LEF1 (0.5% vs
0.8%, P¼ 1.0) and IL7R (0.5% vs 0%, P¼ 1.0) (Supplementary
Material File 1: Supplementary Figures S1 and S2).
The clinical characteristics, cytogenetic subgroups, somatic
mutations with their respective mutational burden, risk classifica-
tion, frontline therapy protocol used, response to therapy, survival
and clinical status of each pediatric and adult patient are
summarised in Supplementary Material File 1: Supplementary
Table S2. Most mutations (88.1%) were detected in B-ALL cases
lacking recurrent fusion genes. In fact, the presence of mutations in
patients with normal cytogenetics was more frequently observed in
both childhood (37.5%) and adult (46.2%) B-ALL cohort
(P¼ 0.002) (Supplementary Material File 1: Supplementary Table
S3). It should be noted that only one pediatric patient (ID10) with
TP53mut harboured the TCF3(E2A)-PBX1 fusion and four patients
(one child, ID13 and three adults, ID25, ID26 and ID34) with
PAX5mut, TP53mut and/or CRLF2mut carried KMT2A(MLL)-R.
Supplementary Material File 1: Supplementary Table S4 details
the frequency of secondary somatic mutations in hotspot regions of
TP53, JAK2, PAX5, LEF1, CRLF2 and IL7R genes classified by
primary chromosomal abnormalities in children and adult patients
with B-ALL. In the entire childhood cohort of B-ALL, all 16
mutations were exclusively detected in the subgroup of patients
without ETV6-RUNX1 (TEL-AML1) translocation (P¼ 0.047).
Moreover, in the entire adult cohort of B-ALL, all 26
mutations were exclusively detected in the subgroup of patients
without BCR-ABL1 translocation (Po0.0001). Thus, none of the
cases with secondary somatic mutations showed ETV6-RUNX1
(TEL-AML1) or BCR-ABL1 translocations as primary chromosomal
abnormalities. There were no other correlations between the
primary chromosomal abnormality and the spectrum of mutations
observed.
Supplementary Material File 1: Supplementary Table S5 details
the primary chromosomal abnormalities evaluated by conven-
tional and molecular cytogenetics, and describes the secondary
somatic mutations according to the number of mutations per
case, their mutational burden, gene-exon mutated and type of
mutation observed in children and adult patients with B-ALL.
The median mutational burden was 24.5% (range, 2–97%) (16.5%
children and 28% adults, P¼ 0.730). It is of particular note that
25.9% of mutations detected showed mutation loads of p10%
(23.5% children and 27% adults, P¼ 1.0), so these variants would
not have been detected by the Sanger capillary sequencing
method (Supplementary Material File 1: Supplementary Table
S2).
Twenty-two of the 30 different mutations found were previously
described in the COSMIC database (http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic) and/or the IARC TP53 database
(http://p53.iarc.fr/p53Sequences.aspx) (Leroy et al, 2014) but we
identified eight undescribed mutations in those genes (one in each
gene under study and three novel missense mutations in PAX5).
Supplementary Material File 1: Supplementary Table S6 showed
the protein domain affected by these mutations. The sequence
analysis revealed 24 missense mutations, three deletion-insertions,
two splicing mutations and one frameshift mutation. As shown in
Supplementary Material File 1: Supplementary Figures S1 and S2,
TP53 mutations were generally distributed across several exons,
with missense mutations being predominantly found in evolutio-
narily conserved regions of this gene. The other mutated genes
showed recurrent mutations: CRLF2 (p.F232C, nine patients),
JAK2 (p.R683G, nine patients and p.R683S, nine patients) and
PAX5 (p.P80R, four patients).
NGS enabled identification of the co-occurrence of mutations
and prediction of the presence or absence of distinct subclones
harbouring different mutations. Eleven out of the 42 patients
with mutations (26.2%) concomitantly harboured more than one
mutation, which were more frequently observed in adult than in
pediatric patients (38.5% vs 6.3%, P¼ 0.030). Ten cases had two
and one adult case had three mutations in the genes investigated.
All of them were orthogoncally validated by other methods such as
Sanger sequencing, re-sequencing run and/or the IonTorrent
sequencer system. Supplementary Material File 1: Supplementary
Table S7 shows the distribution of mutations identified in these 11
patients and Supplementary Material File 1: Supplementary
Table S2 details their clinical characteristics, frontline therapy
and outcome. In four cases (child: ID5 and adults: ID40, ID26 and
ID27), the mutations occurred in the same gene and in the same
amplicon (JAK2, PAX5 or TP53), while one adult patient (ID39)
showed two different mutations within two amplicons of the same
gene (TP53). In five adult cases, mutations occurred in different
genes: three patients (ID17, ID21 and ID42) harboured con-
comitant JAK2 and CLFR2 mutations, while one patient (ID25)
had TP53/PAX5, and other (ID19) CRFL2/LEF1 mutations. Finally,
one adult patient (ID31) harboured three concomitant mutations
in JAK2 and CRLF2, of which two mutations were detected in the
same JAK2 amplicon.
The amplicon-NGS allowed separate subclones to be distin-
guished in two adult patients (ID31 and ID40, Supplementary
Material File 1: Supplementary Figure S3 and Supplementary
Table S2) with the same combination of JAK2 mutations located
in exon 16 (JAK2-E16, p.R683G and p.R683S). In these cases
the mutated codon 683 was not found concomitantly within
the same sequencing read, but was separated across distinct
individual reads. In accordance with the differential mutational
loads between the two JAK2 mutations, the sequencing analysis
demonstrated that the dominant clone harboured the p.R683G
mutation (c.2047A4G), whereas the minority clone harboured the
p.R683S mutation (c.2049A4T). In both cases, the c.2047A4G
mutation was always present at a higher percentage with respect
to the c.2049A4T mutation (patient ID31: 26% and 2%; and
patient ID40: 38% and 4%) and the minority subclone was present
with a mutational burden of o5% of leukaemic cells. Finally,
one of these patients (patient ID31) harboured a third low-
percentage mutation in the CRLF2 gene (p.F232C in 10% of
leukaemic cells).
In addition, amplicon-NGS made it possible to identify clonal
heterogeneity in three patients (one child and two adults) who
carried a double mutation within the same amplicon. In the first
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patient (ID27-adult) who harboured two distinct mutations in
the same amplicon (PAX5-E03, c.215A4G and c.239C4G), 454
deep-sequencing allowed the presence of four lines to be
discriminated; one minority and germline (PAX5wt: 8.8%), one
dominant clone with c.215A4G mutation (51.4%), one subclone
with c. 239C4G mutation (36.6%) and one minority subclone
(3.2%) with a double mutation in the PAX5-E03 gene
(c.215A4G and c. 239C4G) (Supplementary Material File 1:
Supplementary Figure S4). In the second patient (ID5-child) who
carried two mutations in the JAK2-E16 gene, three lines were
identified: one germline (JAK2wt: 84%), one subclone with
c.2044_2045insGGACCTCCTCCCTCC mutation (12%) and one
minority subclone with c.2049A4T mutation (4%)
(Supplementary Material File 1: Supplementary Figure S5).
Finally, three independent lines were identified in the third
patient (ID26-adult) presenting two mutations in the TP53-E08
gene: one germline (TP53wt:83.4%) line, and two minority lines,
one subclone with c.841G4A mutation (10%) and one subclone
with c.845G4C mutation (6.6%) (Supplementary Material File
1: Supplementary Figure S6).
Mutated genes associated with clinical and prognostic features.
Next, mutations were associated with cytogenetic subtypes, clinical
features and risk factors commonly used to stratify pediatric and
adult B-ALL patients (Supplementary Material File 1:
Supplementary Table S8 and Supplementary Table S9). Thus, the
presence of mutations in any of the genes analysed was associated
with children stratified in the high-risk group (P¼ 0.018).
Mutations in the TP53 gene were associated with poor response
to frontline therapy due to refractoriness or relapse events
(P¼ 0.032) (Supplementary Material File 1: Supplementary Table
S8). Meanwhile, in the adult cohort, all 26 mutated cases were
exclusively detected in BCR-ABL1-negative cases (Po0.0001).
The presence of JAK2mut was associated with poor-prognosis
Table 1. Characteristics of pediatric and adult B-ALL patients included in the study
Whole cohort Childreno18 years AdultsX18 years
Characteristics N % n % n % P
All patients 340 100 211 100 129 100 NA
Age at diagnosis (years), median (range) 12 (0–84) 5 (0–17) 45 (18–84) NA
Sex
Male, n (%) 168 49.4 94 44.5 74 57.4 0.022
Female, n (%) 172 50.6 117 55.5 55 42.6
Counts and other parameters
Bone marrow blasta, median (range) 90 (35–100) 90 (35–100) 88 (35–98) 0.011
WBC count (109 l 1), median (range) 15 (1–634) 15 (1–634) 25 (1–575) 0.011
WBC X30109 l1 (%) 112 38.4 59 32.2 53 48.6 0.005
Hb count (g l 1), median (range) 90 (26–172) 76 (26–144) 103 (39–172) o0.0001
Platelet count ( 109 l1), median (range) 53 (2–580) 64 (3–556) 50 (2–580) 0.251
Elevated LDH (U l1) levelb, n (%) 204 85.7 122 84.1 82 88.2 0.386
ECOG score X2, n (%) 22 33.3 5 23.8 17 37.8 0.262
Down syndrome, n (%) 8 2.4 6 2.9 2 1.6 0.715
Cytogenetics
Normal, n (%) 104 30.6 68 32.2 36 27.9 0.401
Abnormal, n (%) 236 69.4 143 67.8 93 72.1
Cytogenetic risk groups
Poor riskc, n (%) 80 23.5 17 8.1 63 48.8 o0.0001
Others, n (%) 260 76.5 194 91.9 66 51.2
Risk groupd
Low risk, n (%) 57 19.3 57 33.9 0 0 o0.0001
Standard (intermediate) risk, n (%) 69 23.3 54 32.1 15 11.7
High risk, (%) 170 57.4 57 33.9 113 88.3
MRD at the end of inductiona
MRD o0.01%, n (%) 165 69.6 119 73.5 46 61.3 0.059
MRD X0.01%, n (%) 72 30.4 43 26.5 29 38.7
Outcome data
SCT performed in first CR, n (%) 48 68.6 21 67.7 27 69.2 0.894
Relapse, n (%) 76 27.7 34 18.1 42 48.8 o0.0001
Very early relapsee, n (%) 41 56.2 13 40.6 28 68.3 0.06
Patients alive in first CR, n (%) 174 65.4 144 84.2 30 31.6 o0.0001
Deaths, n (%) 107 33.5 32 16.3 75 61 o0.0001
Median follow-up (range), months 60 (2–186) 66 (2–186) 39 (3–171) 0.002
5-year OS rates % (95% CI) 68.8 (NR, 60.0–71.5) 85.3 (NR, 77.1–88.5) 40.5 (17, 9.1–24.8) o0.0001
5-year EFS rates % (95% CI) 60.1 (NR, 50.7–62.7) 77.7 (NR, 81.1–68.0) 28.6 (10, 5.3–14.6) o0.0001
5-year RR % (95% CI) 26.1 (NR, 25.1–38.0) 16.1 (NR, 13.2–26.0) 48.1 (70, 50.6–89.5) o0.0001
Abbreviations: B-ALL¼B-cell precursor acute lymphoblastic leukaemia; CI¼ confidence interval; CR¼ complete remission; ECOG¼Eastern Cooperative Oncology Group; EFS¼event-free
survival; HR¼hazards ratio; LDH¼ lactate dehydrogenase; MRD¼minimal residual disease; NA¼ not applicable; NR¼ not reached; OS¼overall survival; RR¼ relapse rate; SCT¼ stem cell
transplantation; WBC¼white blood cell.
Probabilities highlighted in bold indicate statistically significant results (Po0.05).
aBy flow cytometry.
bNormal range: 135–214 IU l 1.
cIncludes patients with t(9;22), t(v;11q23) and hypodiploidy.
dRisk group stratification established according to PETHEMA protocols, based on age, WBC and cytogenetic subgroup.
eTime of relapse criteria: very early, earlier than 18 months after initial diagnosis and less than 6 months after cessation of frontline treatment; early, more than 18 months after initial diagnosis,
but less than 6 months after cessation of frontline treatment; late, more than 6 months after cessation of frontline treatment.
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frontline therapy (P¼ 0.031) (Supplementary Material File 1:
Supplementary Table S9).
Gene mutations are related to a worse outcome. In the survival
analysis of the children, significantly lower OS (5-year OS: 50% vs
86%, P¼ 0.002) and EFS rates (5-year EFS: 50% vs 78.3%,
P¼ 0.009) and higher RR (5-year RR: 33.3% vs 18.6% P¼ 0.037),
were observed in patients with TP53mut compared with patients
without TP53mut (Figure 1 and Supplementary Material file 1:
Supplementary Table S10). The present study also confirmed in
pediatric cohort the well-known associations of particular clinical
and biological variables with worse prognosis, such as the high-risk
group (OS: Po0.0001, EFS: Po0.0001 and RR: P¼ 0.002), MRD
X0.01% (OS: P¼ 0.004 and EFS: P¼ 0.027), WBC X30 109 l 1
(OS: P¼ 0.004), poor-risk cytogenetics due to the presence of
t(9;22), t(v;11q23) or a hypodiploid karyotype (OS: Po0.0001,
EFS: Po0.0001 and RR: P¼ 0.016), age over 10 years (OS:
Po0.0001, EFS: Po0.0001 and RR: Po0.0001), and a Pro-B
phenotype (OS: Po0.0001 and EFS: P¼ 0.004) (Supplementary
Material file 1: Supplementary Table S10). Multivariate analysis of
the group of children showed that TP53mut was an independent
risk factor associated with significantly higher RR (HR¼ 4.5; 95%
CI 1.1–19.2, P¼ 0.04) (Table 2).
In the group of adults, TP53mut had a negative effect on OS
(5-year OS: 0% vs 43.3%, P¼ 0.019) and was associated with a
higher RR (5-year RR: 100.0% vs 61.4%, P¼ 0.029), and JAK2mut
was related with a lower EFS (5-year EFS: 0% vs 30.6%, P¼ 0.035)
and a higher RR (5-year RR: 100% vs 60.4%, P¼ 0.002) (Figure 2
and Supplementary Material File 1: Supplementary Table S11). The
NGS analysis also confirmed the clinical parameters commonly
associated with shorter OS, EFS and RR in adults, such as MRD
X0.01% (RR: P¼ 0.003 and EFS: P¼ 0.023), WBC X30 109 l 1
(RR: P¼ 0.024 and EFS: P¼ 0.008), poor-risk cytogenetic
abnormalities (OS: P¼ 0.013 and EFS: P¼ 0.025) and age X55
years (OS: P¼ 0.001, RR: P¼ 0.027 and EFS: P¼ 0.002).
Supplementary Material File 1: Supplementary Table S11 shows
these clinical parameters commonly associated with shorter
survival in adults. Multivariate analysis of the whole cohort of
ALL adults indicated that the presence of TP53mut was an
independent risk factor associated with significantly shorter OS
(HR¼ 2.3; 95% CI 1.1–5.1, P¼ 0.035). Moreover, TP53mut
(HR¼ 5.9; 95% CI 1.2–28.6, P¼ 0.027) and JAK2mut (HR¼ 5.6;
95% CI 1.1–28.1, P¼ 0.036) retained their independent prognostic
significance in multivariate analysis regarding for RR (Table 3).
Finally, it is worth mentioning that there were no associations
between the mutational burden and the cytogenetic, clinical and
prognostic parameters of the pediatric and adult cohorts with
B-ALL. In the same way, the survival rates of patients who carried
1.0
A B C
n=186, 5-year OS: 86% (95% CI: 78%–89%)
n=4, 5-year OS: 50% (95% CI: 15%–85%)
TP53 wild-type
TP53 mutated
n=184, 5-year EFS: 78% (95% CI: 68%–82%)
n=3, 5-year RR: 33% (95% CI: 6%–79%)
n=4, 5-year EFS: 50% (95% CI: 15%–85%)
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Figure 1. Kaplan–Meier curves for OS, EFS and RR of the whole cohort of children with B-ALL. (A–C) OS, EFS and RR in patients bearing
TP53mut.
Table 2. Univariate and multivariate survival analysis in
children with B-ALL




P HR CI (95%) P
TP53mut 0.002 3.9 0.7–20.1 0.107
Poor risk cytogenetic o0.0001 3.4 0.7–16.0 0.129
WBCX30 109 l1 0.042 1.1 0.4–3.1 0.836
MRDX0.01% 0.004 3 1.1–8.3 0.039
Pro-B B-ALL o0.0001 0.3 0.1–0.9 0.026
JAK2mut 0.0174




P HR CI (95%) P
TP53mut 0.009 2.8 0.6–12.8 0.192
Poor risk cytogenetic o0.0001 2.3 0.7–8.0 0.189
MRD X0.01% 0.027 1.8 0.8–4.0 0.128
Pro-B B-ALL 0.004 0.4 0.2–1.2 0.105
WBC X30 109 l1 0.117
JAK2mut 0.469




P HR CI (95%) P
TP53mut 0.037 4.5 1.1–19.2 0.04
Poor risk cytogenetic 0.016 3.6 1.2–10.5 0.018




Abbreviations: B-ALL¼B-cell precursor acute lymphoblastic leukaemia; CI¼ confidence
interval; EFS¼ event-free survival; HR¼ hazards ratio; MRD¼minimal residual disease;
OS¼overall survival; RR¼ relapse rate; WBC¼white blood cell.
The parameters with P-valueso 0.05 were considered as statistically significant in the
univariate analysis and were included in multivariate analysis. Probabilities highlighted in
bold indicate statistically significant results (Po0.05).
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small clones with p10% of mutational burden did not have
significant differences with respect to those who carried clone sizes
410% (children: 5-year OS: 50% vs 72.7%, P¼ 0.544; 5-year
EFS: 50% vs 72.7%, P¼ 0.606 and 5-year RR: 50.0% vs 20%,
P¼ 0.426; adults: 5-year OS: 0% vs 31.3%, P¼ 0.453 and 5-year
EFS: 0% vs 12.5%, P¼ 0.710). Particularly, for TP53 and JAK2
mutations, there was no difference of mutational burden on
outcome and survival parameters.
CRLF2 overexpression is associated with JAK mutations. Over-
expression of the CRLF2 gene (CRLF2oe) was observed in 17.5% of
B-ALL patients by quantitative RT-PCR assays. There were no
significant differences in the CRLF2oe between child and adult B-ALL
patients (17.3% vs 18.8%, P¼ 1.0). CRLF2oe was common only in
B-ALL cases that lack rearrangements of TEL-AML1, KMT2A(MLL),
TCF3(E2A)-PBX1, and BCR-ABL (P¼ 0.007). Supplementary
Material File 1: Supplementary Table S2 shows the results obtained
from the analysis of CRLF2 expression in each of the patients with
mutations. The presence of JAK2 mutations was associated with
CRLF2oe (P¼ 0.023). Furthermore, neither the clinical nor prognostic
features were associated with CRLF2oe in both childhood and adult
B-ALL patients. However, the survival analysis of whole cohort of
adults with B-ALL showed that the presence of CRLF2oe had a
negative effect on OS (5-year OS: 0% vs 53.8%, P¼ 0.005) and EFS
rates (5-year EFS: 0% vs 33.3%, P¼ 0.006).
DISCUSSION
The presence of gene mutations is a hallmark of B-ALL. In this study,
we evaluated 340 B-ALL cases at diagnosis (211 children and 129
adults) to address the incidence and prognostic impact of TP53, JAK2,
IL7R, PAX5, LEF1 and CRLF2 mutations by NGS. The incidence
(12.4%) and frequency of mutations were higher in adults than in
children according with the better prognosis of pediatric B-ALL. Most
mutations (88.1%) were detected in B-ALL cases lacking recurrent
fusion genes. The incidence and frequency of mutations detected in
our study were similar to observations made in previous ALL studies
(Mullighan, 2011; Pui et al, 2011; Roberts and Mullighan, 2011;
Iacobucci et al, 2012; Loh and Mullighan, 2012; Gowda and Dovat,
2013; Inaba et al, 2013; Chiaretti et al, 2014a, b; Woo et al, 2014). The
use of the NGS strategy further allowed the identification of clonal
heterogeneity in B-ALL patients. A negative impact of the presence of
TP53 and JAK2 mutations on the OS, RR and EFS in patients with
adult and childhood B-ALL was found in the present study.
Therefore, deep sequencing may ultimately be a better guide to
treatment decisions for B-ALL patients.
Among 30 mutations identified at diagnosis, 22 have previously
been described in B-ALL databases (Bercovich et al, 2008; Mullighan
et al, 2009b; Roll and Reuther, 2010; Yoda et al, 2010; Mullighan et al,
2011; Izraeli et al, 2014; Leroy et al, 2014), confirming these mutated
exons to be hotspot regions in leukaemia. Recurrent mutations in
CRLF2 (p.F232C), JAK2 (p.R683G and p.R683S) and PAX5 (p.P80R)
have also been observed in other cohorts of patients with ALL
(Bercovich et al, 2008; Mullighan et al, 2009b; Roll and Reuther, 2010;
Yoda et al, 2010; Mullighan et al, 2011; Izraeli et al, 2014). It is of
particular note that we have found five undescribed mutations in
those genes, three of which are missense mutations in PAX5.
Mutations in the paired box (PAX) domain are predicted as
deleterious, probably impairing the DNA-binding capability of this
lymphoid transcription factor which is essential for normal B-cell
development (Roberts et al, 2001). Also, two undescribed mutations
were found in either IL7R or LEF1, the least frequently mutated genes





































































n=104, 5-year OS: 43% (95% CI: 26%–48%)
n=95, 5-year EFS: 31% (95% CI: 17%–36%)
n=72, 5-year RR: 60% (95% CI: 45%–74%)
n=7, 5-year OS: 0% (95% CI: NC)
n=7, 5-year EFS: 0% (95% CI: NC)









n=4, 5-year RR: 100% (95% CI: NC)




Figure 2. Kaplan–Meier curves for OS, EFS and RR of the whole cohort of adults with B-ALL. (A and B) OS and RR in patients bearing TP53mut.
(C and D) EFS and RR in patients with JAK2mut.
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shown to act as oncogenes in T- and B-ALL (Shochat et al, 2011;
Mazzucchelli et al, 2012). (Shochat et al, 2011). These IL-7R mutations
are usually insertions of bases encoding a cysteine and a proline into
the 6th exon of the extracellular domain, at the border with the
transmembrane region, immediately before or after residue 244
(Mazzucchelli et al, 2012). It is well known that cysteines and prolines
are essential for the constitutive activation of the receptor causing
cytokine independent growth of mouse pro-B cells (Shochat et al,
2011).
In the case of TP53mut, 11 out of 13 patients were negative for
fusion genes, consistent with the findings of a previous ALL cohort
at diagnosis (Chiaretti et al, 2013). Only one pediatric patient (ID10)
with the TCF3(E2A)-PBX1 fusion and one adult (ID26) with
KMT2A(MLL)-R harboured TP53mut. It should be noted that a
significant association between TP53mut and MLL/AFF1 transloca-
tions has been reported (Hof et al, 2011). Furthermore, two patients
with low hypodiploid (ID9 and ID38) and two patients with near
triploid karyotypes (ID22 and ID24) carried TP53 mutations. The
high incidence of TP53 alterations (mutation, deletion) was
previously associated with low hypodiploid/near triploid ALL,
making it possible to distinguish this rare subset from other ALL
subgroups including near haploid ALL. Furthermore, this high
incidence can guide the prognosis of the disease because these
alterations are usually associated with worse prognosis (Muhlbacher
et al, 2014; Stengel et al, 2014). Therefore, the use of NGS could
enable the prognostic B-ALL subgroups of patients to be refined.
Amplicon-based NGS was also able to detect variants with a low
mutational burden, which have been identified in genomic
databases (Bercovich et al, 2008; Mullighan et al, 2009b; Roll and
Reuther, 2010; Yoda et al, 2010; Mullighan et al, 2011; Izraeli et al,
2014; Leroy et al, 2014) or found in previous studies in ALL
patients (Shochat et al, 2011). Thus, our study confirmed that NGS
is a suitable method for accurately detecting and quantifying a
variety of mutations in important genes associated with pathogen-
esis and prognosis of B-ALL. In fact, 26.4% of variations described
in our study had mutation loads of p10%, underlining the high
sensitivity of amplicon-based NGS for detecting small leukaemic
subclones, commonly undetectable by conventional Sanger capil-
lary sequencing. It is well known that mutational screening by
bidirectional Sanger sequencing does not reveal the presence of
mutant subclones representing less than 10–20% of leukaemic cells
(Kastner et al, 2014).
One of the most important tasks in understanding clonal
progression in leukaemia is to assess the nature and number of
different subclones within an individual cancer (Mullighan et al,
2008; Grossmann et al, 2011; Landau et al, 2014) In agreement
with the findings of previous studies (Kohlmann et al, 2010;
Grossmann et al, 2011; Kohlmann et al, 2011; Kastner et al, 2014;
Landau et al, 2014), we confirmed the complex clonal architecture
of ALL. NGS technology allowed the detection of clonal
heterogeneity in some of the analysed patients. This was achieved
by identifying distinct subpopulations with a dominant leukaemic
clone and their relative proportions in the total B-ALL cell
population. The case ID27 (Supplementary Material File 1:
Supplementary Figure S4) shows the presence of leukaemia
subclones that were derived from a common tumour-initiating
cell, whereas cases ID5 and ID26 (Supplementary Material File 1:
Supplementary Figures S5 and S6) have clones with divergent
mutations (Jan and Majeti, 2013). Further investigation with
samples from relapsed ALL is needed to elucidate the effect of these
clones and subclones on disease progression and whether they can
provide clues to the cause of treatment failure (Meyer et al, 2013;
Tzoneva et al, 2013; Lindqvist et al, 2015). Unfortunately these
samples were not available in this study.
The present study showed that TP53 mutations are the mutations
most frequently observed in B-ALL patients. The tumour suppressor
gene TP53 has a crucial role in cell cycle regulation and apoptosis
after DNA damage, and its role in tumorigenesis is well recognised
in solid and haematological malignancies (Chiaretti et al, 2013). In
our study, TP53mut was associated with poor outcome in the whole
cohort of patients and when considering adults and children
separately. These results are in agreement with those of previous
studies in which TP53mut was associated with resistance to
treatment and worse prognosis in several tumours (Olivier et al,
2010; Salmoiraghi et al, 2016). In addition, alterations of the TP53
gene were described as being important at relapse in childhood and
adult ALL, in which they independently predict a high risk of
treatment failure in a significant number of patients (Hof et al,
2011). The presence of TP53 mutations was also associated with a
reduced response rate to induction therapy (Chiaretti et al, 2013)
and a shorter survival (from time of diagnosis and from time of
relapse), even after successful reinduction therapy (Diccianni et al,
1994). These lines of evidence, together with our results, highlight
the importance of sequencing TP53 at diagnosis.
Table 3. Univariate and multivariate survival analysis in adults
with B-ALL




P HR CI (95%) P
TP53mut 0.019 2.3 1.1–5.1 0.035
Poor risk cytogenetic 0.013 1.7 1.1–2.9 0.02









P HR CI (95%) P
JAK2mut 0.035 3.7 0.8–7.1 0.097
Poor risk cytogenetic 0.025 2.3 1.1–4.9 0.028
WBCX30109 l 1 0.008 1.2 0.6–2.5 0.66








P HR CI (95%) P
TP53mut 0.029 5.9 1.2–28.6 0.027
JAK2mut 0.002 5.6 1.1–28.1 0.036
WBC X30109 l 1 0.024 2.2 0.9–5.1 0.072
MRD X0.01% 0.003 2.4 1.1–5.3 0.026
Pro-B B-ALL 0.599
Poor risk cytogenetic 0.988
CRLF2mut 0.412
Abbreviations: B-ALL¼B-cell precursor acute lymphoblastic leukaemia; CI¼ confidence
interval; EFS¼event-free survival; HR¼ hazards ratio; MRD¼minimal residual disease;
OS¼overall survival; RR¼ relapse rate; WBC¼white blood cell. The parameters with
P-values o 0.05 were considered as statistically significant in the univariate analysis and
were included in multivariate analysis. Significant parameters are highlighted in bold.
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JAK2mut was also frequent in B-ALL. JAK2 is an important
mediator of cytokine receptor signalling and has key roles in the
hematopoietic and immune response. Constitutive signalling through
JAK2 contributes to the proliferation of many cancers, including
B-cell leukaemia and lymphomas (Ihle and Gilliland, 2007;
Vainchenker and Constantinescu, 2013). The acquired JAK2mut
(p.R683S and p.R683G) is presumed to be a biomarker for B-ALL
(Bercovich et al, 2008; Mullighan, 2008; Mullighan et al, 2009b).
Recent studies suggested that the amino acid residue p.R683 located
in the linker between the N and C lobes of JH2 domain is important
for maintaining the activity, structural stability and folding of JAK2
(Li et al, 2013). The mutations in p.R683 disrupted the structure of
JH2 domain leading to JAK2 constitutive activation and induced
growth factor-independent cell proliferation of the mouse Ba/F3
hematopoietic cell line (Mullighan, 2008; Li et al, 2013). In our study,
two B-ALL patients with two independent clones each, displayed
different mutations in the p.R683 residue (Bercovich et al, 2008).
Even though the oncogenic effect of p.R683S and p.R683G mutations
could be similar or identical, further research will be necessary to fully
understand the biological relevance of this clonal heterogeneity. The
development of JAK2 inhibitors that abrogates JAK/STAT activation
may be a useful approach for treating patients harbouring these
mutations (Mullighan et al, 2009b; Roberts and Mullighan, 2011).
We found that CRLF2oe is associated with JAK2 mutations in
B-ALL in cases lacking recurrent gene fusions, according to previous
reports (Mullighan et al, 2009a; Yoda et al, 2010; Harvey et al, 2010).
In our study, the frequency of CRLF2oe found in children and adults
was around 17%. While in children it was similar to that observed by
Chen et al (2012), in adults was lower (Chiaretti et al, 2016) even
though maintained its association with poor outcome in this group
of patients. Therefore, CRLF2 quantification could be an important
prognostic marker in adult B-ALL. Evidence from in vitro studies
suggests that these proteins could cooperate to transform B-ALL
cells as CRLF2 acts as a scaffold for JAK2mut signalling (Yoda et al,
2010), although the precise molecular mechanism remains unde-
scribed. However, cells dependent on CRLF2 signalling are also
sensitive to JAK2 inhibitors. Thus, ALL patients with CRLF2oe may
benefit from future kinase inhibitor approaches (Roll and Reuther,
2010; Yoda et al, 2010). Future studies should be conducted to
further elucidate JAK2/CRLF2 association and prognosis in B-ALL.
In this sense, further assessment of gene rearrangements involving
CRLF2 as IGH@-CRLF2 and P2RY8-CRLF2 should be performed to
establish the prognostic significance of CRLF2oe and CRLF2
rearrangements across risk subgroups of B-ALL.
CONCLUSIONS
The amplicon NGS results indicate that the incidence of mutation in
TP53, JAK2, IL7R, PAX5, LEF1 and CRLF2 is higher in adults than
in children. All mutations were frequent in B-ALL cases without
recurrent fusion genes. Given the negative influence on outcome, we
suggest that TP53 and JAK2 status should be investigated at
diagnosis, particularly in patients negative for recurrent fusion genes,
for whom genetic-based prognostic stratification is still limited. Deep
sequencing may ultimately guide treatment decisions better for
B-ALL patients bearing TP53 and JAK2 mutations and could give
rise to alternative therapeutic regimens.
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